GeneTether Therapeutics (XCNQ:GTTX) Equity-to-Asset : 0.97 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. GeneTether Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$1.84 Mil. GeneTether Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was C$1.89 Mil.

The historical rank and industry rank for GeneTether Therapeutics's Equity-to-Asset or its related term are showing as below:

XCNQ:GTTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.72 Med: 0.69 Max: 0.97
Current: 0.97

During the past 4 years, the highest Equity to Asset Ratio of GeneTether Therapeutics was 0.97. The lowest was -1.72. And the median was 0.69.

XCNQ:GTTX's Equity-to-Asset is ranked better than
98.02% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs XCNQ:GTTX: 0.97

GeneTether Therapeutics Equity-to-Asset Historical Data

The historical data trend for GeneTether Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneTether Therapeutics Equity-to-Asset Chart

GeneTether Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

-1.72

0.42

0.96

0.97

GeneTether Therapeutics Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial								0.96	0.94	0.98	0.98	0.97

Competitive Comparison of GeneTether Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, GeneTether Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GeneTether Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneTether Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where GeneTether Therapeutics's Equity-to-Asset falls into.

GeneTether Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

GeneTether Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	1.841	/	1.893
	=

GeneTether Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	1.841	/	1.893
	=

GeneTether Therapeutics (XCNQ:GTTX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

GeneTether Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of GeneTether Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneTether Therapeutics (XCNQ:GTTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3

Website

https://www.genetether.com

GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin.

GeneTether Therapeutics (XCNQ:GTTX) Headlines

No Headlines